Theravance Biopharma (TBPH) SVP has 8,829 shares withheld for RSU tax
Theravance Biopharma (TBPH) SVP Brett A. Grimaud had 8,829 ordinary shares withheld at $16.55 per share to cover taxes on vested restricted stock units. This was a tax-withholding transaction with the company, not an open-market sale. After this transaction, Grimaud directly holds 363,120 ordinary shares.
Theravance Biopharma (TBPH) CEO has shares withheld to cover RSU taxes
Theravance Biopharma CEO Rick E. Winningham reported a routine tax-related share withholding on May 20, 2026. A total of 20,038 Ordinary Shares were withheld at $16.55 per share to cover tax obligations from vesting restricted stock units. This transaction was directly with the company and not an open market sale, leaving Winningham with 1,631,056 directly held Ordinary Shares, along with indirect holdings.
Theravance Biopharma (TBPH) SVP uses 5,678 shares to cover tax bill
Theravance Biopharma SVP Rhonda Farnum disposed of 5,678 Ordinary Shares at $16.55 per share to cover tax obligations related to the vesting of restricted stock units. This was a routine, non-market tax-withholding transaction, not an open-market sale. Following this event, Farnum still directly holds 245,771 Ordinary Shares, maintaining a substantial equity stake in the company.
Behavioral Patterns of TBPH and Institutional Flows
This article analyzes Theravance Biopharma Inc. (NASDAQ: TBPH) using AI models, highlighting a weak near-term sentiment but strong long-term potential. It identifies key support and resistance levels, offering three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles, and emphasizes an exceptional risk-reward setup.
Are Options Traders Betting on a Big Move in Theravance Biopharma Stock?
Options traders are showing significant interest in Theravance Biopharma (TBPH) stock, particularly with the June 18, 2026 $35.00 Call, which exhibits high implied volatility. This suggests market anticipation of a substantial price movement, possibly due to an upcoming event. Analysts also view TBPH favorably, with a Zacks Rank #2 (Buy) and upward revisions in earnings estimates, reinforcing the potential for a significant trade.
BTIG Maintains Theravance Biopharma (TBPH) Buy Recommendation
BTIG has reiterated its Buy recommendation for Theravance Biopharma (TBPH). This reflects a continued positive outlook from the firm regarding the biopharmaceutical company.
Theravance Biopharma: Confident Will Achieve $100 Million Milestone Payment Associated With 2026 Trelegy Net Sales >TBPH
Theravance Biopharma is confident it will achieve a $100 million milestone payment related to 2026 Trelegy net sales. This announcement highlights the company's positive outlook on the commercial performance of its respiratory drug, Trelegy, and its potential financial benefits. The milestone payment is an important financial target for Theravance Biopharma.
Earnings Flash (TBPH) Theravance Biopharma, Inc. Reports Q1 Revenue $17.7M, vs. FactSet Est of $17.8M
Theravance Biopharma, Inc. (TBPH) has reported its first-quarter revenue for 2026, reaching $17.7 million. This figure is slightly below the FactSet estimate of $17.8 million. The company focuses on developing and commercializing medicines for specialty respiratory and neurologic diseases.
Theravance Biopharma (NASDAQ: TBPH) slashes R&D after ampreloxetine trial miss
Following the failure of its Phase 3 CYPRESS study for ampreloxetine, Theravance Biopharma (TBPH) is undergoing a significant restructuring, cutting approximately 50% of its workforce and winding down its R&D function. The company's Q1 2026 financial results showed a narrowed net loss of $4.9 million, driven by increased collaboration revenue from its YUPELRI partnership, which remains its core commercial focus. A Board Strategic Review Committee is actively exploring alternatives for the company's future, including a potential sale, while the company retains up to $100 million in remaining TRELEGY milestone potential.
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. reported strong first-quarter 2026 financial results, with YUPELRI® collaboration revenue increasing 15% year-over-year and all Hatch-Waxman litigation resolved. The company's organizational restructuring and cost reduction initiatives are on track, delivering a significant reduction in operating expenses. A Strategic Review Committee is actively evaluating opportunities to maximize shareholder value, including a potential sale of the company.
Theravance Bio: Q1 Earnings Snapshot
Theravance Biopharma Inc. (TBPH) reported a first-quarter loss of $4.9 million, or 10 cents per share. After adjustments for one-time gains and costs, the company's earnings were 1 cent per share. Revenue for the period was $17.7 million, missing analyst forecasts of $17.9 million.
(TBPH) Movement Within Algorithmic Entry Frameworks
An analysis of Theravance Biopharma Inc. (NASDAQ: TBPH) indicates neutral near and mid-term readings, with a strong long-term positive bias. The stock shows an exceptional 56.6:1 risk-reward setup, targeting a 17.4% gain against a 0.3% risk. Three distinct AI-generated trading strategies are provided: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, tailored for different risk profiles.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
Pomerantz LLP is investigating potential claims against Theravance Biopharma, Inc. (TBPH) on behalf of investors alleging securities fraud or unlawful business practices. This investigation follows a significant stock price drop after Theravance announced its Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint, leading the company to discontinue the program. Investors who suffered losses are encouraged to contact Pomerantz LLP for more information.
Theravance stock declines around 17% in three months: Here's why
The article indicates that Theravance's stock has declined by approximately 17% over the past three months. However, the provided content is empty, so the specific reasons for this decline are not available.
Theravance Biopharma (NASDAQ: TBPH) sets 2026 AGM votes on board, pay, auditor
Theravance Biopharma (NASDAQ: TBPH) has released its agenda for the 2026 Annual General Meeting (AGM), scheduled for June 12, 2026, in Dublin, Ireland. Shareholders will vote on electing six directors to one-year terms, ratifying Ernst & Young LLP as the independent auditor for 2026, and approving a non-binding advisory resolution on executive compensation. The company also announced a reduction in its board size from nine to six members and a full declassification of the board, meaning all directors will stand for annual election.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
Pomerantz LLP is investigating potential securities fraud claims against Theravance Biopharma, Inc. (TBPH) on behalf of investors. This investigation follows a significant drop in Theravance's stock price after the company announced that its Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint, leading to the winding down of the program. Investors affected by the stock price decline are encouraged to contact the law firm.
A Pivotal Quarter for Theravance Biopharma (TBPH): Milestone Cash Influx and a Transition to Pure Commercial Play
Theravance Biopharma (TBPH) reported a significant financial turnaround in Q4 and full-year 2025, driven by substantial milestone payments from YUPELRI and TRELEGY. Following the failure of its CYPRESS study, the company is undergoing a major restructuring to reduce costs and focus entirely on commercializing YUPELRI, projecting considerable annualized cash flow. A strategic review committee is actively exploring value-maximizing alternatives, including a potential sale of the company.
Theravance's Q4 earnings and revenues miss estimates
The article reports that Theravance's Q4 earnings and revenues both missed analyst estimates. No further details are available regarding the specific figures or reasons for the miss.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Moderate Buy" by Brokerages
Theravance Biopharma, Inc. (NASDAQ:TBPH) has received a "Moderate Buy" consensus rating from eight brokerage firms, with an average 12-month price target of $21.83. Recent analyst activity includes upgrades from Zacks and price target increases from B. Riley Financial and TD Cowen, though Weiss Ratings and Oppenheimer downgraded the stock. Insider selling by SVP Rhonda Farnum and significant institutional ownership highlight recent activity around the company.
Theravance and Mylan settle patent dispute with Eugia Pharma
Theravance Biopharma and Viatris (formerly Mylan) have reached a settlement agreement with Eugia Pharma to resolve their ongoing patent infringement lawsuit concerning Yupelri® (revefenacin). This agreement allows Eugia to launch a generic version of Yupelri in the U.S. in 2038, or potentially earlier under certain conditions. The settlement aims to conclude the litigation efficiently while specifying future market entry for a generic alternative.
Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving Average - Here's What Happened
Theravance Biopharma (NASDAQ:TBPH) shares have dropped below their 200-day moving average, trading at $16.57 with a 200-day moving average of $17.19. The company has received mixed analyst ratings, resulting in a "Moderate Buy" consensus with an average target price of $21.83. Insider activity shows SVP Rhonda Farnum selling over 31,000 shares, while institutional investors hold a significant portion of the stock.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Theravance Biopharma, Inc. (TBPH) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Theravance Biopharma, Inc. (NASDAQ:TBPH) shareholders following the failure of the company's CYPRESS trial. The law firm is encouraging investors who purchased Theravance securities to connect to assist in the investigation. The investigation stems from Theravance reportedly spending millions on operations during the trial's enrollment phase, which ultimately failed.
Theravance Biopharma, Inc. (TBPH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Theravance Biopharma, Inc. (TBPH) securities. The investigation follows Theravance's report of significant operational expenses during its CYPRESS trial's enrollment phase, which ultimately failed. The law firm is encouraging affected investors to contact them to learn more and potentially assist in a class action lawsuit to recover capital.
Theravance Biopharma, Inc. (TBPH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Theravance Biopharma, Inc. (TBPH) following the failure of its CYPRESS trial. The firm is encouraging investors who purchased Theravance securities to contact them to learn more about potential claims regarding the company's financial practices during the high-risk trial. The investigation focuses on whether the company's significant spending on operations expenses during the enrollment phase of this ultimately failed trial could lead to claims for investors.
Theravance Stock Declines Around 17% in Three Months: Here's Why
Theravance Biopharma (TBPH) has seen its stock decline by nearly 17% over the past three months due to the failure of its lead pipeline candidate, ampreloxetine, in a pivotal Phase III study. This setback has led the company to reassess strategic options, including a potential sale and a major organizational restructuring involving significant workforce reductions and the shutdown of its R&D division. The company's reliance on collaboration revenues and lack of wholly-owned commercial products further contributes to investor uncertainty.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Theravance Biopharma, Inc. (TBPH) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased securities of Theravance Biopharma, Inc. (TBPH). The investigation follows Theravance's report of significant operational expenses for its high-risk CYPRESS trial, which ultimately failed. The firm encourages affected investors to connect to learn more about assisting the investigation, which seeks to recover investor capital and ensure corporate accountability.
Here's why Theravance Biopharma (TBPH) is a strong momentum stock
This article identifies Theravance Biopharma (TBPH) as a strong momentum stock, likely based on its recent stock performance and technical indicators. It suggests that investors interested in growth opportunities might find TBPH appealing.
Bronstein, Gewirtz & Grossman, LLC Encourages Theravance Biopharma, Inc. (TBPH) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Theravance Biopharma, Inc. (TBPH) securities. This investigation follows the company's report of significant operational expenses during its CYPRESS trial enrollment phase, which ultimately failed. Investors who purchased Theravance securities are encouraged to contact the firm to learn more and assist with the investigation, as Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis.
Tudor Investment Corp ET AL Sells 145,515 Shares of Theravance Biopharma, Inc. $TBPH
Tudor Investment Corp ET AL significantly reduced its stake in Theravance Biopharma (NASDAQ:TBPH) by 74.0%, selling 145,515 shares in Q3 and retaining 51,048 shares valued at $745,000. Insider Rhonda Farnum also sold 31,067 shares, decreasing her holding by 11.78%. Analyst sentiment is mixed but leaning positive, with Zacks and Wall Street Zen upgrading TBPH to "Strong-Buy" and HC Wainwright raising its price target to $27, while a legal investigation by Pomerantz LLP could introduce volatility.
Theravance Biopharma (TBPH) price target decreased by 39.48% to 16.49
The article reports that the price target for Theravance Biopharma (TBPH) has been significantly decreased by 39.48% to a new target of $16.49. This indicates a notable downgrade in analyst expectations for the company's stock performance.
Theravance Biopharma (TBPH) price target decreased by 39.48% to 16.49
This article reports a significant 39.48% decrease in the price target for Theravance Biopharma (TBPH), bringing it down to $16.49. The content from MSN was likely a brief financial news update detailing this change.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Theravance Biopharma, Inc. (TBPH) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against Theravance Biopharma, Inc. (NASDAQ:TBPH) after the company reported significant operational expenses during its failed CYPRESS trial. Investors who purchased Theravance securities are encouraged to learn more and potentially assist in the investigation. The law firm represents investors in class actions on a contingency fee basis.
Theravance Biopharma, Inc. (TBPH) Investigation: Bronstein, Gewir
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Theravance Biopharma, Inc. (TBPH) securities. This investigation follows the company's report of significant operational expenses and the subsequent failure of its CYPRESS trial, which represented a major cash burn on a high-risk program. Shareholders are encouraged to contact the firm to learn more and assist with the investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
Pomerantz LLP is investigating potential securities fraud claims against Theravance Biopharma, Inc. (NASDAQ: TBPH) on behalf of investors. This investigation follows the company's announcement on March 3, 2026, that its Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint, leading to a significant drop in Theravance's stock price. Investors who suffered losses are encouraged to contact the firm.
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Theravance Biopharma (TBPH)
This article summarizes analyst ratings for Neurocrine (NBIX) and Theravance Biopharma (TBPH). Wolfe Research reiterated a Buy rating for Neurocrine with a $160 price target, aligning with a Strong Buy consensus and a $184.05 average target. For Theravance Biopharma, B. Riley Securities maintained a Hold rating with a $17 price target, reflecting a Moderate Buy consensus and a $16.61 average target.
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Theravance Biopharma, Inc. (TBPH) for potential securities law violations after the company reportedly spent millions on its high-risk CYPRESS trial, which ultimately failed. The investigation focuses on whether Theravance issued false or misleading statements and failed to disclose critical information to investors. Shareholders who suffered losses are encouraged to contact the firm to discuss their rights.
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating claims on behalf of Theravance Biopharma, Inc. (NASDAQ: TBPH) investors for potential securities law violations. The investigation stems from concerns that Theravance made misleading statements regarding significant operational expenses during its high-risk CYPRESS trial, which ultimately failed. Shareholders who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights.
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Theravance Biopharma, Inc. (TBPH) for alleged securities law violations. The investigation centers on the company's significant spending on operations during the enrollment phase of its high-risk CYPRESS trial, which ultimately failed, suggesting potentially misleading statements or undisclosed information to investors. Shareholders who experienced losses are encouraged to contact the firm.
TBPH: B. Riley Securities Raises Price Target to $17.00, Maintai
B. Riley Securities has raised its price target for Theravance Biopharma (TBPH) to $17.00 from $14.00, while maintaining a Neutral rating. This update comes amidst other recent analyst adjustments for the biopharmaceutical company, including a maintained Buy rating from BTIG at $21.00 and a downgrade from Oppenheimer. Theravance Biopharma currently has an "Outperform" consensus recommendation from brokerage firms, with an average target price of $16.60.
B. Riley Raises Price Target on Theravance Biopharma to $17 From $14, Keeps Neutral Rating
B. Riley has increased its price target for Theravance Biopharma (TBPH) to $17 from $14, while maintaining a Neutral rating on the stock. This adjustment comes despite a recent downgrade by B. Riley on March 4th, which lowered the rating to Neutral from Buy and decreased the price target at that time. The article also notes recent news regarding the company's Q4 operating income and the failure of its Phase 3 CYPRESS study.
Theravance Biopharma (TBPH) CFO receives 37,500-share equity grant in Form 4
Theravance Biopharma's SVP & Chief Financial Officer, Aziz Sawaf, was granted 37,500 Ordinary Shares on April 1, 2026, as outlined in a Form 4 filing. These shares were awarded at a price of $0.00, indicating compensation rather than a market purchase. Following this grant, Mr. Sawaf directly holds 353,623 Ordinary Shares in the company.
Theravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street Zen
Wall Street Zen has downgraded Theravance Biopharma (NASDAQ:TBPH) from a "strong-buy" to a "buy" rating. The company's stock opened at $16.02, has a market capitalization of $824.87 million, and a P/E ratio of 7.89. Despite the downgrade, other analysts maintain a "Moderate Buy" consensus with an average target price of $21.33, reflecting mixed views, while an insider recently sold shares.
JPMorgan Chase & Co. Purchases 93,591 Shares of Theravance Biopharma, Inc. $TBPH
JPMorgan Chase & Co. significantly increased its stake in Theravance Biopharma (TBPH) by 78.3%, acquiring an additional 93,591 shares to hold a total of 213,104 shares valued at $3.11 million. This increase in institutional investment comes as analysts have shown more positive sentiment, with several upgrading the stock to "buy" or "strong-buy" and setting an average price target of $21.33. Despite some insider selling, the biopharmaceutical company's stock currently trades around $16.02, with a market capitalization of approximately $824.92 million.
Theravance Biopharma (TBPH) CEO awarded 75,000 Ordinary Shares
Theravance Biopharma's CEO, Rick E. Winningham, was awarded 75,000 Ordinary Shares at no cost, which was recorded as a grant or acquisition. Following this grant, his direct holdings increased to 1,651,094 Ordinary Shares, in addition to indirect holdings through a custodian and a trust. This transaction is considered a compensation-related award rather than a market purchase and reflects no stock sales by the CEO.
Theravance Biopharma (TBPH) SVP awarded 18,750 shares in Form 4 filing
Rhonda Farnum, SVP of Commercial & Medical Affairs at Theravance Biopharma, Inc. (TBPH), was awarded 18,750 Ordinary Shares on April 1, 2026, as compensation. These shares were granted at $0.00 per share, increasing her direct holdings to 251,449 Ordinary Shares. This transaction, filed on a Form 4, reflects an increase in her equity-based compensation within the company.
Theravance Biopharma (TBPH) SVP receives 37,500-share equity grant
Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc. (TBPH), received a grant of 37,500 Ordinary Shares on April 1, 2026, as compensation. These shares were awarded at $0.00 per share, increasing his direct holdings to 371,949 Ordinary Shares. This transaction is characterized as a routine equity grant, not an open-market purchase, and therefore has weaker signaling value regarding market trading decisions.
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro
The Multiple System Atrophy (MSA) market is projected for significant growth, from USD 44 million in 2025 to USD 1,753 million by 2034, driven by advancements in therapies from companies like Alterity Therapeutics, Ionis Pharmaceuticals, and Biohaven Pharmaceuticals. The US currently holds the largest market share, with Germany leading in EU4 and the UK. The report highlights upcoming therapies and stresses the increasing prevalence and awareness of this rare neurodegenerative disorder as key market drivers.
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Theravance Biopharma, Inc. (NASDAQ: TBPH) for potential securities law violations. The investigation stems from the company's significant spending on its high-risk CYPRESS trial, which ultimately failed, leading to concerns about false or misleading statements to investors. Shareholders who incurred losses are encouraged to contact the Schall Law Firm to discuss their rights.
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Theravance Biopharma, Inc. (NASDAQ: TBPH) for potential securities law violations. This investigation stems from allegations that the company made false or misleading statements and failed to disclose critical information to investors, particularly regarding significant operational expenses during its ultimately failed CYPRESS trial. Shareholders who suffered losses are encouraged to contact the law firm to discuss their rights.
TBPH PE Ratio & Valuation, Is TBPH Overvalued
This article analyzes the valuation of Theravance Biopharma Inc (TBPH), concluding that it is currently undervalued. Based on a relative valuation method, TBPH's fair price is estimated to be between $84.42 and $93.72, significantly higher than its current price of $16.02. The analysis also compares TBPH's P/B ratio, FCF yield, and P/S ratio against its historical averages and industry competitors.
